US07725L1026
© BusinessWire
23.12.2025
ONC
LISTED
NASDAQ
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST.
Live webcasts of these events can be accessed from the investors section of the Company’s website at ht...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2025
ONC
LISTED
NASDAQ
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression o...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ONC
LISTED
NASDAQ
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
08.12.2025
ONC
LISTED
NASDAQ
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematolo...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
26.11.2025
ONC
LISTED
NASDAQ
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) m...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2025
ONC
LISTED
NASDAQ
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, advances its vision to become the world’s leading oncology company with extensive new data from its differentiated hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, December 6-9. Nearly 50...
Themefolio
Profiler
Peergroup
© BusinessWire
17.11.2025
ONC
LISTED
NASDAQ
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line tre...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ONC
LISTED
NASDAQ
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025.
“These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said John V. Oyler, Co-Foun...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2025
ONC
LISTED
NASDAQ
BeOne Medicines to Present at Upcoming Investor Conferences
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at two upcoming investor conferences:
Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 9:30 am EST; and
Jefferies Global Healthcare Conference in London on Mon...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
ONC
LISTED
NASDAQ
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2025 financial results on Thursday, November 6, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.
The live webcast of this even...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ONC
LISTED
NASDAQ
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in B...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ONC
LISTED
NASDAQ
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, for the treatment of adult patients with relaps...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
29.08.2025
ONC
LISTED
NASDAQ
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), followi...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
ONC
LISTED
NASDAQ
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved TEVIMBRA (tislelizumab), in combination with platinum-containing chemotherapy as neoadjuvant treatment followed by TEVIMBRA monotherapy as adjuvant treatment, for adult patients with resectable non...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2025
ONC
LISTED
NASDAQ
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, with a fireside chat at 1:50 p.m. EDT.
The live webcast of this event can be accessed from the investors section of the Company’s website...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
ONC
LISTED
NASDAQ
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding China, of Amgen’s IMDELLTRA® (tarlatamab-dlle) for up to $950 million to Royalty Pharma (Nasdaq: RPRX).
Under the terms of the agreement, BeOne will...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2025
ONC
LISTED
NASDAQ
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved a new film-coated tablet formulation of BRUKINSA® (zanubrutinib) for all approved indications.
"Developed to meet the real-world needs of patients, the new BRUKINSA tablet formulation aims to simplify...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
ONC
LISTED
NASDAQ
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to the Company’s investigational Bruton’s tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of patients with Waldenstrom’s macroglobulinemia...
Themefolio
Profiler
Peergroup
© BusinessWire
28.07.2025
ONC
LISTED
NASDAQ
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with platinum-containing chemotherapy as neoadjuvant tre...
Themefolio
Profiler
Peergroup
© BusinessWire
16.07.2025
ONC
LISTED
NASDAQ
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.
The live webcast of this even...
Themefolio
Profiler
Peergroup
© BusinessWire
10.07.2025
ONC
LISTED
NASDAQ
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curat...
Themefolio
Profiler
Peergroup
© BusinessWire
26.06.2025
ONC
LISTED
NASDAQ
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
News Preview
In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today’s investor R&D Day. The event comes at a pivotal moment for the Company, which has more than 40 clinical and commercial stage a...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
ONC
LISTED
NASDAQ
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of a new film-coated tablet formulation of BRUKINSA® (zanubrutinib) for all approved indications. Th...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
ONC
LISTED
NASDAQ
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
ONC
LISTED
NASDAQ
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA® (zanubrutinib) for all five approved indications. BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across al...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
ONC
LISTED
NASDAQ
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will host an Investor R&D Day in New York City and via webcast on June 26, 2025 at 8:30 am ET. John V. Oyler, Co-Founder, Chairman, and CEO of BeOne, along with the Company's leadership team and distinguished key opinion leaders, wi...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
ONC
LISTED
NASDAQ
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules...
Themefolio
Profiler
Peergroup
© BusinessWire
31.05.2025
ONC
LISTED
NASDAQ
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation sta...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
ONC
LISTED
NASDAQ
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
News Preview
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company formerly known as BeiGene, Ltd., today announced its new name and redomiciliation to Switzerland are officially in effect, marking a significant milestone in the Company’s evolution.
This press release features multimedia. View the full release here: https://w...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
ONC
LISTED
NASDAQ
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with gemcitab...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
ONC
LISTED
NASDAQ
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share 23 abstracts featuring new data across its hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, May 30 – June 3, 2025. W...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
ONC
LISTED
NASDAQ
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
ONC
LISTED
NASDAQ
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT.
The live webcast of this event can be accessed from the investors sect...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
ONC
LISTED
NASDAQ
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.
“We delivered another exceptional quarter, achieving our first quarter of GAAP profitability with continued global revenue growth....
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
ONC
LISTED
NASDAQ
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) tha...
Themefolio
Profiler
Peergroup
© BusinessWire
17.04.2025
ONC
LISTED
NASDAQ
BeiGene to Announce First Quarter 2025 Financial Results on May 7
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
ONC
LISTED
NASDAQ
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.
The Independent Data Monitoring Committee r...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
ONC
LISTED
NASDAQ
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with et...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
ONC
LISTED
NASDAQ
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresecta...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
ONC
LISTED
NASDAQ
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced financial results and corporate updates from the fourth quarter and full year 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
ONC
LISTED
NASDAQ
BeiGene to Present at Upcoming Investor Conferences
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Company will participate in fireside chats at two upcoming investor conferences:
TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 am ET; and
Leerink Par...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
ONC
LISTED
NASDAQ
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
ONC
LISTED
NASDAQ
BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe
News Preview
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1st. This appointment will enhance the Company’s commitment to bring impactful medicines to mor...
Themefolio
Profiler
Peergroup
© BusinessWire
27.12.2024
ONC
LISTED
NASDAQ
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unre...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
ONC
LISTED
NASDAQ
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally.
“As we enter our 15th year, changin...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2024
ONC
LISTED
NASDAQ
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhi...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
ONC
LISTED
NASDAQ
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today announced the presentation of new clinical data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring its leadership in chronic lymphocytic leukemia/small lymphocytic...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
ONC
LISTED
NASDAQ
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced its new partnership with CLL Society, the world’s leading authority for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) cancer patients. Together, they are advancing Test...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
ONC
LISTED
NASDAQ
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will host an investor webcast on December 16, 2024 at 8:30 am EST. The Company’s R&D leadership team will provide an update on BeiGene’s innovative portfolio and pipeline, focusing on key...
Themefolio
Profiler
Peergroup
© BusinessWire
27.11.2024
ONC
LISTED
NASDAQ
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesop...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
ONC
LISTED
NASDAQ
BeiGene to Present at Upcoming Investor Conferences
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will participate in fireside chats at two upcoming investor conferences:
Citizens JMP Hematology and Oncology Summit on Monday, December 2 at 1:00 p.m. ET; and
Citi’s Global Healthcare...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2024
ONC
LISTED
NASDAQ
Labcorp CFO Glenn Eisenberg Announces Plans to Retire
News Preview
Julia Wang Named Chief Financial Officer Beginning December 2, 2024
BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang wil...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
ONC
LISTED
NASDAQ
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company which intends to change its name to BeOne Medicines Ltd., today announced it has entered into a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. resolving patent litigation related to MSN’s Abbreviated New Drug Application (ANDA)...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
ONC
LISTED
NASDAQ
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible.
This press release features...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
ONC
LISTED
NASDAQ
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112799807/en/(Graphic: Business Wire)
“Our exceptional third-quar...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
ONC
LISTED
NASDAQ
BeiGene to Present at the Jefferies London Healthcare Conference
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies London Healthcare Conference on November 20, 2024, with a fireside chat at 2:30 p.m. GMT.
The live webcast of this event can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com, h...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
ONC
LISTED
NASDAQ
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and assets, including best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib), at the 66th ASH Annual Meeting and Exposition in San Diego, December 7-10. BeiGene has...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2024
ONC
LISTED
NASDAQ
BeiGene Mourns Death of Beloved Board Member Donald Glazer
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to share the news that Donald Glazer recently passed away. Don was a Board member and the chair of the nominating and corporate governance committee.
Co-founder, Chairman and CEO John V. Oyler issued the following statement:
“We are saddened by the pas...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2024
ONC
LISTED
NASDAQ
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued positive opinions recommending an extended authorization for TEVIMBRA® (tislelizumab) in gastric or gastroesophageal junction (G/GEJ) adenocarcinom...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
ONC
LISTED
NASDAQ
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
News Preview
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research from studies evaluating BRUKINSA® (zanubrutinib), Bruton tyrosine kinase (BTK) chimeric degradation activation compound (CDAC) degrader BGB-16673 and B-cell lymphoma 2 (BCL2) inhibitor sonrotoclax in patients with Waldenström’s...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
